Loading
Trials recruiting now, the landmark trials, the trials held by this cancer's subtypes, the key papers and what they mean, the latest literature, and the milestones year by year.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
An option with a demonstrated survival benefit for transplant-ineligible relapsed diffuse large B-cell lymphoma, a group for whom very little has ever shown one. The fatal adverse event imbalance belongs in the conversation alongside the survival figure.
Reading several mutations on one fragment pushes detection below one part per million in lymphoma, where such clustered mutations are common. It has not been shown in breast cancer, where they are rarer.
The evidence behind the United States approval of brentuximab vedotin with lenalidomide and a rituximab product for relapsed or refractory diffuse large B-cell lymphoma after two or more lines in patients not eligible for an autologous transplant or CAR-T. It is also the first demonstration that a CD30-directed conjugate helps in a disease where CD30 expression is variable.
A lower-middle-income country can design, manufacture, trial and approve an autologous CAR-T therapy. Response rates are in the range of first-generation Western products in similar mixed populations, at a price an order of magnitude lower, which reopens the question of what CAR-T should cost everywhere.
It is the evidence base for CARTHEDRALL, the multicentre trial meant to bring a national CAR-T to Brazil's public health system at a fraction of the price of imported products.
CD20 x CD3 bispecifics gave patients whose lymphoma has failed CAR-T, or who cannot access it, an effective off-the-shelf treatment that can be started within days. Epcoritamab and glofitamab are now standard third-line options and are moving into earlier lines and combinations. They do not yet replace CAR-T, whose remissions appear more durable.
Gene expression, not only mutation, can be inferred from blood, and the method keeps some accuracy below 1 per cent tumour DNA. That is still far above residual-disease levels.
POLARIX gave the first new first-line standard for DLBCL since rituximab was added to CHOP, and pola-R-CHP is now approved and widely used, especially in higher-risk or ABC-type disease. The gain is modest and survival is unchanged, so many clinicians still use R-CHOP in lower-risk or GCB-type patients. Cost and subgroup uncertainty drive ongoing debate.
Query for this cancer: (TITLE:"Diffuse large B-cell lymphoma" OR ABSTRACT:"Diffuse large B-cell lymphoma") AND (treatment OR therapy OR trial OR survival OR diagnosis). Results are unfiltered search hits about Diffuse large B-cell lymphoma, not a curated reading list.
Cyclophosphamide, doxorubicin, vincristine, prednisone becomes the backbone for aggressive lymphoma.
Rituximab added to CHOP raises cure rates by ~15 points; the standard for the next twenty years.